ANN 101
Alternative Names: ANN-101Latest Information Update: 23 Jun 2025
At a glance
- Originator Anodyne Nanotech
- Class Obesity therapies
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Obesity
Most Recent Events
- 23 Jun 2025 ANN 101 is available for licensing as of 23 Jun 2025. https://www.theheropatch.com/
- 23 Jun 2025 Anodyne Nanotech has patents pending for microneedles and microneedle patches for transdermal drug delivery and methods of making and using the same in USA, Israel, Europe, South Korea, Japan, Australia, Mexico, Brazil, Canada and worldwide
- 09 Jun 2025 Preclinical trials in Obesity in USA (Transdermal) before June 2025 (Anodyne Nanotech pipeline, June 2025)